tbuckley/cabot-search huggingface dataset:
Index
Journal: Cardiovascular Research (1999)

ACE inhibitors (42) 733 Aspirin (42) 824 Acetylcholine (41) 299, (41) 765 Atherosclerosis (41) 323, (41) 334, (41) 361, (41) 376, (41) 385, Action potential (42) 298 (41) 395, (41) 402, (41) 443, (41) 458, (41) 465, (41) 473, Acute coronary syndromes (42) 240, (41) 334, (41) 402, (42) (41) 746 824 AT1 receptors (41) 109 Adenosine A receptors (42) 57 1 ATP (41) 166 Adenylate cyclase (42) 607 ATP phosphorylation potential (42) 149 1 Adenylyl cyclase (42) 87 ATP-sensitive K channels (41) 629 Adhesion molecules (41) 443 Atrial fibrillation (42) 298, (42) 434, (42) 443, (42) 477 Adrenal catecholamines (42) 201 Atrial myocytes (41) 166 Adrenergic agonists (42) 490 Atrial natriuretic factor (41) 731 Adrenergic blockade (42) 183 Atrium (42) 470, (42) 706 Adrenergic receptor (42) 48 Autonomic nervous system (42) 65 b-adrenergic receptors (42) 121, (42) 627 Adrenoceptor agonists (41) 220 Balloon angioplasty (41) 489 b -Adrenoceptor overexpression (42) 173 2 Baroreceptor (42) 183 b-Adrenoceptors (41) 116 Bcl-2 (41) 109 Adrenomedullin (41) 731 Bcl6 (42) 670 Adventitia (41) 255 Benzocaine (42) 510 Aging (41) 307, (41) 554, (41) 594, (41) 682 Beta-adrenergic receptors (42) 434 Aldose reductase (42) 130 Blood flow (41) 87, (42) 627 Angiogenesis (41) 663 Blood pressure (42) 201, (42) 206 Angiography (41) 746 Bovine (41) 237 Angioplasty (42) 761 Bradycardia (42) 15 Angioscopy (41) 458 Angiotensin II (41) 109, (42) 761 11 Ca entry (41) 282 Angiotensin II AT receptor blockade (41) 100 1 21 Ca uptake (41) 135 Angiotensins (41) 532, (41) 746, (42) 660 21 Ca / calmodulin-dependent protein kinase II (42) 254 Angiotensin-converting enzyme (41) 544 21 Ca -handling proteins (42) 443 Anoxia (41) 109, (41) 147 Ca-current (42) 402 Antiarrhythmia agents (41) 563 Cadmium (41) 188 Antiarrhythmic agents (41) 212 Caffeine (42) 149 Antiarrhythmic drugs (42) 298, (42) 503 Calcium (cellular) (41) 175, (42) 636, (42) 794 Anticoagulants (41) 418 Calcium antagonist (42) 752 Antiheart antibodies (41) 116 Calcium channel blocker (41) 299 Antihypertensive agents (42) 773 Calcium current (42) 391 Antihypertensive therapy (41) 299 Calcium current, L-type (42) 113 Antioxidant (41) 385 cAMP (42) 113 Antiplatelet therapy (41) 418 cAMP-dependent protein kinase (42) 254 Anti-adrenoceptor antibodies (41) 116 Apoptosis (41) 109, (41) 147, (41) 361, (41) 473, (41) 480, (42) Carbon monoxide (41) 385 805 Cardiac action potential (41) 611 L-Arginine (41) 765 Cardiac contractility (41) 611 Arginine-vasopressin (42) 201 Cardiac diseases (42) 706 Arrhythmia mechanisms (41) 175, (41) 563, (42) 477, (42) 530 Cardiac dysfunction (41) 116 Cardiac electrophysiology (42) 434 Arrhythmias (41) 212, (42) 361, (42) 455 Cardiac function (41) 586 Arterial distensibility (41) 701 Cardiac myocytes (42) 104, (41) 200
Diphenylhydantoin in emotional disorders
Authors: S. Livingston
Journal: JAMA (1968)

<h3>To the Editor:—</h3> I was appalled by a lengthy article (<i>Life Magazine</i>, Sept 29, 1967) entitled "10,000-to-1 Payoff" which describes "miraculous" control of various types of behavioral aberrations with diphenylhydantoin (DPH). Written by a nonmedical person, it relates the opinions and findings of another nonmedical reporter about the effectiveness of diphenylhydantoin in the treatment of behavioral disorders, and the toxicity of this drug. In the<i>Life</i>article, there are many inaccurate statements. A reporter asked his personal physician, "Is it (DPH) a dangerous drug?" The physician is quoted as having replied: "One of the safest.... there are occasional side effects, of course, but they are rare and generally minor and they go away if the medicine is stopped." The reporter comments: "DPH simply makes you feel normal. It does not sedate or tranquilize you. It does not pep you up. We have yet to read or hear of anyone ever
Session G: Miscellaneous
Authors: C Arcara, F Fulfaro, R Anastasio, A Malato, S Siragusa, L Lo Coco, N Gebbia, G Astara, E Massa, F Tanca, G Gramignano, M Lusso, A Stara, C Madeddu, G Mantovani, C Augello, V Gregorio, P Cammareri, S Cascio, A Gullo, V Agnese, V Calo, S Corsale, L Bruno, G Gargano, G Rocca, P Sisto, S Restivo, V Morello, R Tomasino, M Buscemi, A Gerbino, A Martorana, E Daniele, V Bazan, A Russo, A Bonacchi, L Bellotti, D Dallera, M Cerruti, G Paolini, A Rossi, F Francini, A Barontini, M Rosselli
Journal: Annals of Oncology (2005)
Species Differences in Metabolism of Heterocyclic Aromatic Amines, Human Exposure, and Biomonitoring
Authors: Robert J. Turesky, Gian A. Gross, W. G. Stillwell, Paul L. Skipper, Steven R. Tannenbaum
Journal: Environmental Health Perspectives (1994)

Heterocyclic aromatic amines (HAAs) are animal carcinogens and suspected human carcinogens which are formed in cooked foods at the low parts per billion level.HAAs in cooked meats were purified by either immunoaffinity chromatography or solid phase tandem extraction, which allowed for the simultaneous analysis of 11 HAAs by HPLC.The metabolism of two prominent HAAs, 2-amino-3,8-dimethylimidazol4,5-f]quinoxaline (MelQx) and 2-amino-3-methylimidazo[4,5-flquinoline (IQ), was investigated in animal models and in vitro with human tissues to develop strategies for human biomonitoring.MelQx and 10 are rapidly absorbed from the gastrointestinal tract of rodents and transformed into several detoxification products which are excreted in urine and feces.Metabolites result from cytochrome P450-mediated ring oxidation at the C-5 position followed by conjugation to sulfate or f-glucuronic acid.Other major metabolites include the phase 11 conjugates, N -glucuronide and N -sulfamate.A metastable N2-glu- curonide conjugate of the genotoxic metabolite of /N-hydroxy-MelQx was also detected in urine and bile.The binding of both carcinogens to blood proteins was low and suggests that human biomonitoring through protein adducts may be difficult.These metabolic pathways exist in nonhuman primates and several of these pathways also occur in vitro with human liver.The urinary excretion of MelQx in seven human subjects following con- sumption of cooked beef or fish ranged between 2 and 22 ng in 12 hr when determined by negative ion chemical ionization GC-MS.After acid hydrolysis of urine, the amount of MelQx increased 4-to 1 0-fold in 6 of the 7 subjects.These acid labile metabolites were identified as the N2-sulfamate and N 2-glucuronide following column chromatography and HPLC purification.Thus, amine sulfamation and N 2-glucuronidation are important routes of detoxification of MelOx in rodents, nonhuman primates, and humans.
Mutations of the SF3B1 splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness
Authors: Davide Rossi, Alessio Bruscaggin, Valeria Spina, Silvia Rasi, Hossein Khiabanian, Monica Messina, Marco Fangazio, Tiziana Vaisitti, Anna Guarini, Ilaria Del Giudice, Michaela Cerri, Stefania Cresta, Clara Deambrogi, Ernesto Gargiulo, Valter Gattei, Francesco Forconi, Francesco Bertoni, Silvia Deaglio, Raul Rabadan, Laura Pasqualucci, Robin Foà, Riccardo Dalla-Favera, Gianluca Gaidano
Journal: Blood (2011)
Diseases of the Eye.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leibesübungen mit Körperbeschädigten: Ein Lehr- und Arbeitsbuch für Körperbehinderte und ihre Betreuer
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mortality and duration of hemodialysis treatment
Authors: P. J. Held
Journal: JAMA (1991)

Decrease in the average duration of hemodialysis treatment time is a continuing phenomenon. We investigated the relationship of 3-year mortality to duration of dialysis in a 1984-1985 national random sample of 600 hemodialysis patients from 36 dialysis units. Mortality was negatively associated with duration of dialysis treatments, as shown by the Cox model, adjusted for other patient and dialysis unit covariates. With adjustment for other covariates, patients receiving an average dialysis treatment duration of less than 3.5 hours had relative mortality risks of 1.17 to 2.18 compared with those with treatments longer than 3.5 hours (mortality risk of 1.0). Reverse causation (the possibility that more seriously ill patients received dialysis for a shorter time) appears unlikely. We conclude that duration of the dialysis procedure is an important element in determining patient mortality as one of the factors determining the adequacy of dialysis. (<i>JAMA</i>. 1991;265:871-875)
Canadian Journal of Surgery, Toronto
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Periodic Ataxia
Authors: Wilberto DeCastro
Journal: JAMA (1967)

IN 1946 Parker<sup>1</sup>described a bizarre but clearcut symptom complex consisting of acute transient general cerebellar dyssynergia, affecting all muscles of the body, including those of articulation. These attacks last no longer than a few seconds to a few minutes, and disappear just as suddenly as they come on. The patient then reverts to his former condition, normal or otherwise. He described 11 cases, six associated with some phase of multiple sclerosis. The condition in another four was due to familial cerebellar ataxia, but their periodic attacks were more violent and bitterly complained of. One unusual case was an instance of degenerative spinocerebellar ataxia. This syndrome was termed "periodic ataxia." In 1959, Andermann et al<sup>2</sup>studied two patients with multiple sclerosis who had paroxysmal attacks of dysarthria and ataxia. The cardinal features were the sudden paroxysmal occurrence and brief duration of the attacks.<sup>3</sup>The cerebellum or its connections
Thymidylate synthase polymorphism in the development of Barrett's associated adenocarcinoma
Authors: H. Kuramochi, J. H. Peters, K. Uchida, S. Schneider, D. Vallboehmer, D. Shimizu, P. T. Chandrasoma, K. D. Danenberg, T. R. Demeester, P. Danenberg
Journal: Journal of Clinical Oncology (2004)

9528
Normal Values for Pancreozymin-Secretin Test
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14757: Prognostic Significance of Tissue Oxygen Saturation Using Near Infrared Spectroscopy in Patients Undergoing Therapeutic Hypothermia After Cardiac Arrest
Authors: Adrian Bell, Ataul Qureshi, Stephen O Awuor, Sanjeev Nair, Agei Enoh, Daniel Makowski, Charity Curtis, Nainesh C Patel, Bruce A Feldman
Journal: Circulation (2015)

Background: Near infrared spectroscopy is a noninvasive method for assessing regional tissue oxygenation (StO2), a parameter influenced by microvascular perfusion. Normal StO2 values recorded from the thenar eminance are 87% ± 6%. In critically ill patients, low StO2 levels (&lt;70%) have been associated with a poor prognosis. We evaluated the prognostic significance of StO2 in patients undergoing therapeutic hypothermia (TH) after cardiac arrest (CA). Hypothesis: After resuscitation from CA, an initial StO2 ≥70%, or an initial StO2 &lt;70% followed by an upward trend, is associated with a good neurologic outcome. Methods: We conducted a retrospective analysis of CA patients who underwent TH between August, 2005 and June, 2013. StO2 levels at the thenar eminence were collected at the onset and hourly during TH. Neurological outcome was assessed by the Cerebral Performance Category (CPC) at hospital discharge. Good outcome was defined as survival to hospital discharge with a CPC ≤2. Univariate and multivariate analyses were performed. Results: Among 160 patients, 18% (n=29) survived with a CPC ≤2. Survival with a CPC ≤2 was associated with witnessed CA (p=0.04; OR 11.6; 95% CI 1.1-118.0), shockable rhythm (p=0.02; OR 3.4; 95% CI 1.2-9.3), time to return of spontaneous circulation (ROSC) ≤15 minutes (p=0.02; OR 4.5; 95% CI 1.2-16.6) and age &lt;65 (p=0.001; OR 7.6; 95% CI 2.3-25.5). However, an initial StO2 ≥70% was not associated with a CPC ≤2 (P=0.7; OR 0.82; 95% CI 0.29-2.2). For patients with an initial St02 &lt;70%, there was no difference in outcome between those with an upward trend vs downward trend in St02 (p=0.98). Conclusions: Similar to previous trials documenting the value of TH witnessed CA, shockable rhythm, short time to ROSC, and younger age were associated with a good neurologic outcome. StO2 levels recorded from the thenar eminence were not associated with neurologic outcome. These StO2 levels are influenced by regional perfusion and tissue oxygenation but may not reflect cerebral microvascular perfusion. Identifying alternative technologies to assess cerebral microvascular perfusion may help determine patients for whom a good neurologic outcome can be predicted.
HORROR AUTOTOXICUS AND OTHER CONCEPTS OF PAUL EHRLICH
Authors: J. H. T.
Journal: JAMA (1961)

The story of Paul Ehrlich as related by Martha Marquardt<sup>1</sup>is replete with scientific accomplishments and amply documented with personal experiences of the internationally famous German physician. Although Ehrlich led an abundant life, he is best remembered for his development of the spirocheticide arsphenamine ("606" or Salvarsan). The side-chain theory, concepts of immunity, aversion to the possibility of auto-antibodies—<i>horror autotoxicus</i>—development of organic dyes with histologic specificity, and the ability to apply the fruits of scientific investigation to the diagnosis and treatment of disease reflect the masterworks of a brilliant mind. Ehrlich was born in Upper Silesia in Eastern Germany in 1854, the beginning of the Golden Age of intellectual supremacy of German scientific thought, basic and applied. His parents were prosperous citizens; his father was an innkeeper. Latin and mathematics came easy in<i>Gymnasium</i>, but he was an indifferent student. German composition was particularly difficult—especially letters to
Drugs
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poetry and Medicine
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Down's syndrome with myelodysplastic syndrome showing t(7;11)(p13;p14)
Authors: H Ohnishi, T Taki, K Tabuchi, M Kobayashi, F Bessho, Y Hayashi
Journal: American Journal of Hematology (2000)

We report a boy with Down's syndrome (DS) who developed myelodysplastic syndrome (MDS) after spontaneous remission of transient myeloproliferative disorder (TMD) at birth. Chromosomal analysis of the blasts in the MDS phase demonstrated t(7;11)(p13;p14) which had not been detected in the TMD phase. NUP98-HOXA9 chimera mRNA, which is known to be involved in t(7;11)(p15;p15) translocation in acute myeloid leukemia (AML), was not detected by reverse transcriptase-polymerase chain reaction, and NUP98 rearrangement was not detected by Southern blot analysis of the blasts in the MDS phase. Reciprocal translocation is very rare in AML/MDS in DS, and the t(7;11)(p13;p14) found in our patient was different from the recurrent translocation t(7;11)(p15;p15) previously reported.
Instructions to authors and Information for readers
Authors: David Cohen
Journal: Hepatology (2018)

Observations in Hepatology submissions are intended to be outstanding case-based contributions which describe a unique presentation, novel observation, or cutting edge approach to management of a liver disease.The format should not include an abstract.It should include a brief introduction, presentation of the case (or case series), and discussion.The maximum length is 750 words, including the summary and references.There is a maximum of 2 figures or tables, and 5 references.
Ganciclovir
Authors: Clyde S. Crumpacker
Journal: New England Journal of Medicine (1996)

Ganciclovir is a nucleoside analogue of guanosine, a homologue of acyclovir, and the first antiviral drug to be effective in the treatment of cytomegalovirus (CMV) disease in humans.14 It inhibits not only all the herpesviruses but also the transformation of normal cord-blood lymphocytes by Epstein–Barr virus.57 In this review, I outline ganciclovir's mechanisms of action and resistance and discuss the clinical effectiveness of intravenous and oral ganciclovir.Mechanism of ActionThe structures of ganciclovir and of its analogue acyclovir are shown in Figure 1. In vivo, ganciclovir is converted to ganciclovir triphosphate, which inhibits viral DNA polymerases, including those . . .